An open label, phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity

Journal of Drugs in Dermatology

Volumn 14, Issue 6, 2015, Pages 560-564

  Carrasco, Daniel ^a   Stecher, Michael ^b   Lefebvre, Gigi Claire ^c   Logan, Alan C ^d   Moy, Ronald ^e  

^a Austin Dermatology Associates   (United States)

^b XBiotech USA Inc   (United States)

^c Meridien Research   (United States)

^d CAMN Research Consulting   (United States)

^e Moy Cosmetic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MABP1; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; INTERLEUKIN 1ALPHA; MABP1 MONOCLONAL ANTIBODY;

ACNE VULGARIS; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INJECTION SITE ERYTHEMA; MALE; MODIFIED BODY IMAGE DISTURBANCE QUESTIONNAIRE; MONOTHERAPY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; QUESTIONNAIRE; SELF CONCEPT; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ANXIETY; BODY IMAGE; CLINICAL TRIAL; DEPRESSION; PSYCHOLOGICAL ADJUSTMENT; PSYCHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANXIETY; BODY IMAGE; DEPRESSION; DERMATOLOGIC AGENTS; EMOTIONAL ADJUSTMENT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1ALPHA; MALE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84930791207     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol. 1997; 38 (3):115.
2. Collier CN, Harper JC, Cafardi J.A., Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008; 58 (1):56.
3. Dalgard F, Gieler U, Holm JØ, Bjertness E, Hauser S. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. J Am Acad Dermatol. 2008; 59 (5):746.
4. Cotterill JA, Cunliffe WJ Br. Suicide in dermatological patients. J Dermatol. 1997; 137 (2):246.
5. Bowe, W.P. & Logan, A.C. Acne Vulgaris, probiotics and the gut-brain-skin axis - back to the future? Gut Pathongens. 2011, 3:1.
6. Stokes JH, Pillsbury DH. The effect on the skin of emotional and nervous states: theoretical and practical consideration of a gastrointestinal mechanism. Arch Dermatol Syphilol. 1930, 22:962-93.
7. Guy R., et al. The Effects of Inflammatory Cytokines on the Isolated Human Sebaceous Infundibulum. J Invest Dermatol 110: 410-415, 1998.
8. Guy R., et al. Modeling Acne in Vitro. J Invest Dermatol. 106:176-182, 1996.
9. Kim J., et al. Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses. The Journal of Immunology. 2002, 169: 1535-1541.
10. Graham G.M., et al. Proinflammatory cytokine production by human kerati-nocytes stimulated with Propionibacterium acnes and P. ances GroEL. British Journal of Dermatology. 2004; 150: 421-428.
11. Jeremy A., et al. Inflammatory Events Are Involved in Acne Lesion Initiation. J Invest Dermatol. 121: 20-27, 2003.
12. Hong DS et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15 (6):656-66.
13. Cash, T.F., Phillips, K.A., Santos, M.T, & Hrabosky, J.I. (2004). Measuring "negative body image:" Validation of the body image disturbance questionnaire in a non-clinical population. Body Image: An International Journal of Research. 1, 363-372.
14. Cash, T.F., & Grasso, K. (2005). The norms and stability of new measures of the multidimensional body image construct. Body Image: An International Journal of Research. 2, 199-203.
15. Bowe WP Doyle AK, Crerand CE, Margolis D.J., Shalita AR. Body image disturbance in patients with acne vulgaris. J Clin Aesthet Dermatol. 2011 Jul; 4 (7):35-41.
16. Bjelland I., Dahl A., Haug T., Neckelmann D. The validity of the Hospital Anxiety and Depression Scale an updated literature review. Journal of Psychosomatic Research. 52 (2002) 69-77.
17. Yazici K, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol. 2004 Jul; 18 (4):435-9.
18. Bito T, et al. Influence of neutralizing antibodies to adalimumab and infiximab on the treatment of psoriasis. Br J Dermatol. 2014 Apr; 170 (4):922-9. doi:10.1111/bjd.12791.
19. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014 Feb; 170 (2):261-73. doi:10.1111/bjd.12654.I
20. Le Chatleier, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013; 500:541-46.
21. Bowe WP. Probiotics in acne and rosacea. Cutis. 2013 Jul; 92 (1):6-7
22. Cunliffe WJ, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997; 194 (4):351-7
23. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. 2008 Sep; 27 (3):197-206. doi:10.1016/j.sder.2008.07.002.